Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
|
|
TFF Pharmaceuticals, Inc. (TFFP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 10/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/17/2023 |
4
| CARLSON CAPITAL L P (10% Owner) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Sold 215,000 shares
@ $0.4374, valued at
$94k
Sold 1,000 shares
@ $0.3916, valued at
$391.6 |
|
| 08/17/2023 |
3
| CARLSON CAPITAL L P (10% Owner) has filed a Form 3 on TFF Pharmaceuticals, Inc. |
| 08/16/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/15/2023 |
4
| Weisman Harlan F (President and CEO) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 600,000 shares
@ $0.25, valued at
$150k
|
|
| 08/15/2023 |
4
| ROCAMBOLI STEPHEN (Director) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 20,000 shares
@ $0.25, valued at
$5k
|
|
| 08/15/2023 |
4
| Roberts Brandi (Director) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 20,000 shares
@ $0.25, valued at
$5k
|
|
| 08/15/2023 |
4
| COLEMAN KIRK ALLEN (CFO) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 20,000 shares
@ $0.25, valued at
$5k
|
|
| 08/15/2023 |
4
| MILLS ROBERT S (Director) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 40,000 shares
@ $0.25, valued at
$10k
|
|
| 08/15/2023 |
4
| Mikhak Zamaneh (Chief Medical Officer) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 120,000 shares
@ $0.25, valued at
$30k
|
|
| 08/15/2023 |
8-K
| Quarterly results|
Docs:
|
"UNDERWRITING AGREEMENT",
"OPINION OF GREENBERG TRAURIG, LLP",
"TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock FORT WORTH, Texas, August 14, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or a...",
"TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock FORT WORTH, Texas, August 15, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it has priced its underwritten public offering of 19,896,000 shares of its common stock at a public offering price of $0.25 per share. All of the securities in the underwritten public offering are to be sold by the Company. The Company expects the gross proceeds from this offering to be $4.97 million, before deducting the underwriting discount and other estimated offering expenses. The Company has granted the underwriter a 30-day option to purchase up to 2,984,400 add...",
"TFF PHARMACEUTICALS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Grant revenue $ 333,351 $ 28,004 $ 384,780 $ 95,439 Operating expenses: Research and development 2,681,898 5,102,090 6,700,557 10,339,514 General and administrative 2,670,363 3,678,119 5,789,579 6,891,317 Total operating expenses 5,352,261 8,780,209 12,490,136 17,230,831 Loss from operations Other income : Interest income 36,120 5,880 71,199 13,065 Change in fair value of note receivable - - Total other income , net 5,880 33,783 13,065 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average common shares outstanding, basic and diluted 36,193,085 25,373,706 36,193,085 25,372,749 5 TFF PHARMACEUTICALS, INC. CON...",
"THE COMPANY'S CORPORATE UPDATE AND PRESENTATION MATERIALS" |
|
| 08/14/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/24/2023 |
4
| COLEMAN KIRK ALLEN (CFO) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.8, valued at
$80k
|
|
| 03/13/2023 |
4
| ROCAMBOLI STEPHEN (Director) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 13,000 shares
@ $0.8025, valued at
$10.4k
|
|
| 03/13/2023 |
4
| COLEMAN KIRK ALLEN (CFO) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 12,000 shares
@ $0.7881, valued at
$9.5k
|
|
| 03/13/2023 |
4
| Weisman Harlan F (President and CEO) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 150,000 shares
@ $0.8789, valued at
$131.8k
|
|
| 03/13/2023 |
4
| Mikhak Zamaneh (Chief Medical Officer) has filed a Form 4 on TFF Pharmaceuticals, Inc.|
Txns:
| Bought 15,000 shares
@ $0.82, valued at
$12.3k
|
|
| 03/08/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/07/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Lung Therapeutics, Inc. reports a 2.1% stake in TFF Pharmaceuticals, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 02/09/2023 |
SC 13G/A
| CARLSON CAPITAL L P reports a 5.1% stake in TFF Pharmaceuticals, Inc. |
| 01/20/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 01/11/2023 |
8-K
| Quarterly results |
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|